Trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) reduces triglyceride (TG) levels in adipocytes through multiple pathways, with AMP-activated protein kinase (AMPK) generally facilitating, and peroxisome proliferator-activated receptor c (PPARc) generally opposing these reductions. Sirtuin 1 (SIRT1), a histone/protein deacetylase that affects energy homeostasis, often functions coordinately with AMPK, and is capable of binding to PPARc, thereby inhibiting its activity. This study investigated the role of SIRT1 in the response of 3T3-L1 adipocytes to t10c12 CLA by testing the following hypotheses: 1) SIRT1 is functionally required for robust TG reduction; and 2) SIRT1, AMPK, and PPARc cross regulate each other. These experiments were performed by using activators, inhibitors, or siRNA knockdowns that affected these pathways in t10c12 CLA-treated 3T3-L1 adipocytes. Inhibition of SIRT1 amounts or activity using siRNA, sirtinol, nicotinamide, or etomoxir attenuated the amount of TG loss, while SIRT1 activator SRT1720 increased the TG loss. SRT1720 increased AMPK activity while sirtuin-specific inhibitors decreased AMPK activity. Reciprocally, an AMPK inhibitor reduced SIRT1 activity. Treatment with t10c12 CLA increased PPARc phosphorylation in an AMPK-dependent manner and increased the amount of PPARc bound to SIRT1. Reciprocally, a PPARc agonist attenuated AMPK and SIRT1 activity levels. These results indicated SIRT1 increased TG loss and that cross regulation between SIRT1, AMPK, and PPARc occurred in 3T3-L1 adipocytes treated with t10c12 CLA.
Introduction
Conjugated linoleic acid (CLA) reduces adiposity in human and mouse adipocytes [1] [2] [3] [4] , and the trans-10, cis-12 CLA (t10c12 CLA) isomer is capable of causing this response [5] . The rates of fatty acid oxidation and lipolysis increased in t10c12 CLA-treated 3T3-L1 adipocytes [6] , while lipolysis increased and fatty acid biosynthesis decreased in t10c12 CLA-treated human adipocytes [7, 8] . Molecular responses to t10c12 CLA include the activation of AMP-activated protein kinase (AMPK) [9] , integrated stress response (ISR; [10, 11] ) or unfolded protein response (UPR; [12] ), mitogen-activated protein kinase (MAPK) cascades [7] , and attenuation of peroxisome proliferator-activated receptor c (PPARc) protein levels [3] . Treatment with t10c12 CLA requires nuclear factor kappa-B (NF-kB) for an inflammatory response [3, 4, 10, [13] [14] [15] that includes increased prostaglandin biosynthesis in human adipocytes [11] , in mouse white adipose tissue [16] , and 3T3L1 adipocytes [17] . Despite this progress in understanding of the pathways involved in the early perception of t10c12 CLA and the complex regulation of the subsequent responses, much remains unknown in this process.
AMPK is a central regulator of cellular energy levels that is activated by increases in the cellular AMP/ATP ratio, various cellular stresses [18, 19] , or treatment of adipocytes [9] or mice [20] with t10c12 CLA or mixed isomers of CLA. AMPK activation requires phosphorylation at Thr172 [21] , and two of the target proteins inhibited by phosphorylation by AMPK are acetyl-CoA carboxylase (ACC), and fatty acid synthase, two key enzymes in fatty acid biosynthesis. Through this and other mechanisms [18, 19] , activated AMPK decreases lipogenesis, increases fatty acid oxidation, and increases lipolysis in adipocytes in vitro and in vivo [22] . Phenformin and metformin are structurally related chemicals that can be used to activate AMPK [18, 23] . Metformin increases TG loss in t10c12 CLA treated adipocytes, while compound C, a potent inhibitor of AMPK, attenuates TG loss in this system [9] .
PPARc is a ligand-activated nuclear receptor that regulates lipogenesis and is a key regulatory point for controlling inflammation in adipocytes [24] . PPARc forms a complex with nuclear receptor corepressors 1 or 2 (NCoR1 or 2) in the absence of its bound ligand [25] . PPARc transactivation activity is also reduced by phosphorylation at Ser112 by extracellular signal-regulated kinase (ERK), c-Jun N-terminal Kinase (JNK), or p38 MAPKs, and a phosphorylation-dependent sumoylation at K107 [26] . In addition, a non-genomic role for PPARc is emerging, as a number of PPARc-dependent processes are too rapid to involve transcriptional responses [27, 28] . The critical role of PPARc in the response to t10c12 CLA is demonstrated by the attenuated responses that occur on addition of PPARc agonists [11, 29, 30] .
Protein deacetylation is emerging as an important mechanism for regulating energy balance [31, 32] . Of the two major classes of histone/protein deacetylases in mammals, the NAD-dependent class III sirtuins are structurally and enzymatically distinct from those of the zinc-dependent class I/II deacetylases [33] . Within the seven members of the sirtuin family, SIRT1 (sirtuin 1) is particularly involved in regulating cell energy metabolism, cell stress, and cell fate [34] . SIRT1 directly binds to NCoR1 and directly or indirectly to PPARc to repress PPARc transactivation activity, inhibit adipogenesis, and increase fat loss in adipocytes [35] . SIRT1 deacetylates liver kinase B1 (LKB1), facilitating the ability of LKB1 to phosphorylate AMPK, defining a SIRT1/ LKB1/AMPK signaling pathway that provides one of the connections between SIRT1 and AMPK for regulating energy metabolism [36, 37] . SIRT1 also deacetylates NF-kB, thereby modulating NF-kB transactivation activity [38, 39] . Amongst the chemicals that affect the activity of sirtuins, the activator SRT1720 preferentially activates SIRT1 [40] , while sirtinol and nicotinamide are used as general sirtuin inhibitors that do not inhibit class I/II deacetylases [41] . Nicotinamide is a direct product of the sirtuin deacetylation reaction that inhibits sirtuin enzymes as a non-competitive product inhibitor [42] . Etomoxir indirectly inhibits sirtuin activity as it inhibits fatty acid transport into mitochondria which prevents an increase in NAD + , an activator of sirtuin activity [43] .
In this study, we analyzed the functional role of SIRT1 in the attenuation of TG levels in t10c12 CLA-treated 3T3-L1 adipocytes. Our objectives were to test whether SIRT1 was functionally required for robust triglyceride reduction, and whether SIRT1, AMPK, and PPARc cross regulated each other in the response. These experiments were performed with activators, inhibitors, or siRNA that affected these pathways and analyzing their effects on TG levels, fatty acid metabolism, and post-translational modifications or activity levels of SIRT1, AMPK, and PPARc.
Experimental Procedures

Reagents
Compound C was purchased from Calbiochem (San Diego, CA). Bovine serum albumin (BSA, .99% fat free), dexamethasone, etomoxir, GW9662, insulin, isobutyl-1-methylxanthine, metformin, nicotinamide, phenformin, and sirtinol were purchased from Sigma (St. Louis, MO). Ciglitazone, pioglitazone, rosiglitazone, and troglitazone were from Fisher (Pittsburgh, PA). SRT1720 was from Cayman Chemical (Ann Arbor, MI). T10c12 CLA (90%, #UC-61-A) was from Nu-Chek Prep, Inc (Elysian, MN). Antibodies to acetyl-NF-kB p65 (acetyl K310), p-PPARc (phospho S112) and negative control siRNA were from Abcam (Austin, TX). Protein A agarose beads, antibodies to b-actin, NCoR1, NF-kB p65, PPARc, SIRT1, anti-goat or anti-rabbit secondary antibodies coupled to horseradish peroxidase, and Sirt1 siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to p-AMPK, AMPK, p-ACC, and ACC were from Cell Signaling (Beverly, MA). T7 RNA polymerase (P2077) and rNTPs (E6000) were purchased from Promega. SiRNA to lamin A/C, non-target siRNA, and DharmaFECT Duo transfection reagent (T-2010-02) were from Dharmacon (Thermo Fisher Scientific, Boulder, CO).
3T3-L1 cell culture, differentiation, and chemicals
Low passage 3T3-L1 fibroblasts [44] were obtained (H. Green, Harvard Medical School) and cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) containing 10% bovine calf serum (Fisher, Pittsburgh, PA) and differentiated as described [9] . When present, chemicals were dissolved in DMSO, with the exception that 2 mmol/L metformin and 0.1 mmol/L phenformin were dissolved in water, and were added directly to the media at #0.2% of the final volume in the media. An initial chemical concentration was determined from literature values and a range of concentrations around this value were then tested for their effects in vivo. From this data, the lowest effective concentration was chosen and used at the following concentrations: 5 mmol/L ciglitazone, 10 mmol/L compound C, 10 mmol/L etomoxir, 10 mmol/L GW9662, 10 mmol/L nicotinamide, 5 mmol/L pioglitazone, 5 mmol/L rosiglitazone, 10 mmol/L sirtinol, 8 mmol/L SRT1720, or 5 mmol/L troglitazone and were added 1 h before adding fatty acids. Fatty acids, either linoleic acid or trans-10, cis-12 CLA, were dissolved in 0.1 M KOH, diluted into fatty acid free (.99%) bovine serum albumin (BSA) in phosphate buffered saline at a 1:1 ratio (2 mmol/L BSA: 2 mmol/ L fatty acid), pH adjusted to 7.4, and added to the cultures containing 4 to 6 d post-differentiated 3T3-L1 adipocytes [9] . We used 50 mM t10c12 CLA if assaying chemicals that increased TG loss, but otherwise used 100 mM t10c12 CLA.
Fatty acid biosynthesis, oxidation, and lipolysis assays )] to the media for 4 h, after which time the plates were washed four times with PBS, and specific experimental media treatments were initiated. Media (0.1 ml) was collected after 24 h, lipids extracted in 1 ml of 2:1 chloroform:-methanol [45] and measured by scintillation counting. The use of labeled [ 14 C]-acetate and the 2:1 chloroform:methanol extraction step considerably reduced non-specific background to 50 DPM, as determined by using the above protocol on cells that had been briefly exposed to 37 KBq [
14 C]-acetate in media.
siRNA transfections
For siRNA transfections, 3T3-L1 adipocytes, 4 to 5 d post differentiation, were transfected by siQUEST transfection reagent (Mirus, Madison, WI) or DharmaFECT Duo transfection reagent (Dharmacon, Thermo Fisher Scientific, Boulder, CO) as described [47] . For siQUEST transfections, concentrations of 2 ml of siQUEST reagent per ml of media and 40 nmol/L of siRNA were added 24 h before adding fatty acids. For DharmaFECT Duo transfections, concentrations of 1.4 ml per cm 2 of Dharma-FECT Duo and 80 nmol/L of siRNA were added 24 h before adding fatty acids.
T7 transcription of oligonucleotide templates
In addition to commercially available siRNAs, we utilized siRNAs derived from transcription of oligonucleotide templates with T7 RNA Polymerase as described [48] . The siRNA sequences used were: siRNA control sequence: 59-AAC AGU CGC GUU UGC GAC UGG UCU CUU GAA CCA GUC GCA AAC GCG ACU GCC UAU AGU GAG UCG UAU UA-39. LaminA/C siRNA sequence: 59-AAG GAG GAG CUU GAC UUC CAG UCU CUU GAA CUG GAA GUC AAG CUC CUC CCC UAU AGU GAG UCG UAU UA-39. Sirt1 siRNA: 59-AAG GAG ACU GCG AUG UUA UAA UCU CUU GAA UUA UAA CAU CGC AGU CUC CCC UAU AGU GAG UCG UAU UA-39
Immunoblot analysis
Nuclear and cytosolic extracts were isolated using a nuclear extract kit (Active Motif, Carlsbad, CA). Equal amounts of proteins from whole cell, nuclear, or cytosolic extracts were separated by SDS-PAGE, transferred to Immun-blot PVDF membrane (Bio-Rad Laboratories, Hercules, CA), probed with the indicated primary antibodies, and detected with secondary antibodies. Enhanced chemiluminescence (Pierce, Rockford, IL) was used for detection. Band intensities were determined from digital images from exposures in the linear range using software (Quantity One, Biorad, Hercules, CA). All western blot analyses were repeated at least three times.
Immunoprecipitation
Immunoprecipitations were performed according to the procedure described [35] . In brief, the collected 3T3-L1 adipocytes were sonicated, lysates were centrifuged, and aliquots of the supernatants were immunoprecipitated overnight with specific antibody or control nonspecific IgG serum. Protein A agarose beads were used to bind the specific or non-specific antibody complexes, the protein A beads containing bound proteins were washed five times, and the bound proteins were eluted in SDS sample buffer for immunoblot analysis.
Quantification of TG content
Cell isolation and TG measurements were performed according to the manufacturer's instructions using TG reagent (T2449; Sigma, St. Louis, MO) and free glycerol reagent (F6428; Sigma, St. Louis, MO). TG data are expressed as nmol of TG per mg of protein.
Measurement of MCP-1 and COX2 mRNA
Total RNA was extracted by TRIzol (Invitrogen) following the manufacturer's protocol. Total RNA (2 mg) was used for cDNA synthesis. Real-time PCR was performed by a Bio-Rad iCycler using iQ SYBR Green Supermix reagent (Bio-Rad, Hercules, CA) using PCR primers for MCP-1 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [9] , and COX2 [9] . MCP-1 and COX2 mRNA levels were normalized to GAPDH, which showed no significant variation in microarray analyses between linoleic acid and t10c12 CLA treatments. Experiments were repeated three times, and each sample was analyzed using one RNA control and two replicates of each cDNA pool, and the relative amounts of MCP-1, COX2 and GAPDH were calculated using the comparative C T method [49] , according to the manufacturer's software (Bio-Rad, Hercules, CA). Cycle numbers were used to calculate gene expression levels in the log linear amplification range.
Statistical Analysis
One or two-way ANOVA was used to analyze the data. Posthoc pairwise comparisons were calculated using Tukey's test and were considered significant for p#0.05. All analyses were performed using SAS software (SAS, Cary, NC).
Results
SIRT1 is required for reduced TG levels in t10c12 CLAtreated adipocytes
We first determined whether increased SIRT1 activity would affect TG levels in t10c12 CLA-treated differentiating adipocytes. To specifically activate SIRT1, we used SRT1720, as this chemical is known to preferentially activate SIRT1 at 8 mM [40] . SRT1720, in combination with 50 mM t10c12 CLA, significantly lowered TG to levels below those achieved by 50 mM t10c12 CLA alone (Fig. 1A) . In contrast, addition of 100 mM t10c12 CLA in combination with a sirtuin inhibitor, either sirtinol or nicotinamide, significantly increased TG levels, relative to those from adipocytes treated with 100 mM t10c12 CLA alone ( Fig. 1. B) . Etomoxir, which inhibits sirtuin activity indirectly by reducing NAD + levels via inhibition of mitochondrial fatty acid transport and oxidation [43] , was also tested. Treatment with etomoxir and t10c12 CLA significantly increased TG levels relative to TG levels with t10c12 CLA alone (Fig. 1C) . These data supported a hypothesis that one or more sirtuins participate in the TG loss response caused by t10c12 CLA treatment, and that SIRT1 involvement was likely due to the response to SRT1720, a specific SIRT1 activator.
SiRNA was used to reduce SIRT1 expression to confirm the functional involvement of SIRT1 in the response to t10c12 CLA. First, to verify that SIRT1 protein levels were likely to respond to siRNAi-mediated knockdown of its mRNA levels in t10c12 CLAtreated adipocytes, the half-life of SIRT1 in cycloheximide treated adipocytes was determined to be less than 6 h ( Figure S1 ) and that treatment with t10c12 CLA did not change SIRT1 protein levels ( Figure S2 ). We additionally verified that our siRNA transfection method could deliver siRNA efficiently enough to knockdown protein levels of Lamin A/C ( Figure S3 ), a target known to be susceptible to siRNA knockdown in adipocytes [47] .
A siRNA targeted against SIRT1 mRNA significantly reduced SIRT1 protein levels but did not affect b-actin levels, while a control non-target siRNA did not change SIRT1 or b-actin amounts (Fig. 1D ). In the presence of t10c12 CLA, siRNA knockdown of SIRT1 in adipocytes produced higher levels of TG levels than those from adipocytes treated with a non-target siRNA or reagent only controls (Fig. 1E) . In the presence of LA, the siRNA SIRT1 treated adipocytes had TG levels that were not significantly different than those from adipocytes treated with the control non-target siRNA or reagent (Fig. 1E) . These results indicate that siRNA knockdown of SIRT1 attenuated the TG loss caused by t10c12 CLA. Taken together with the above inhibitor studies, these results demonstrate that inhibition of SIRT1 activity or protein levels significantly interfere with the TG loss caused by t10c12 CLA. Further, the magnitude of the change in TG levels in the inhibitor studies (Figures 1b and 1c) and when SIRT1 was knocked down by siRNA (Figure 1e ) indicates SIRT1 accounts for most or all of the SIRT activity involved in lipid loss in t10c12 CLA treated adipocytes.
SIRT1 affects the rates of fatty acid metabolism and the inflammatory response
The involvement of SIRT1 in t10c12 CLA-mediated changes in the rates of fatty acid biosynthesis, oxidation, and lipolysis as well as in the induction of two key inflammatory mRNAs was then measured to gain insight into how SIRT1 affected these specific pathways. Adipocytes treated with t10c12 CLA alone had a 77% reduction in their rate of lipogenesis ( Fig. 2A) . The combination of t10c12 CLA and sirtinol significantly changed this to a 47% reduction in the rate of lipogenesis ( Fig. 2A) . This result indicated SIRT1 activity was involved in inhibiting the rate of fatty acid biosynthesis. Adipocytes treated with t10c12 CLA exported significantly more radioactively-labeled lipids than LA treated cells, but the amount of t10c12 CLA-mediated lipolysis was not significantly affected by the sirtuin inhibitor sirtinol (Fig. 2B) . The rate of fatty acid oxidation was significantly increased in t10c12 CLA-treated adipocytes, and although fatty acid oxidation was less when sirtinol was added, this difference was not significant (Fig. 2C ). In conclusion, it appears the major change in lipid metabolism affected by SIRT1 is the rate of fatty acid biosynthesis.
The inflammatory MCP1 and COX2 mRNAs were highly induced by t10c12 CLA treatment ( Fig. 2D-E) . The SIRT1 activator SRT1720, in combination with t10c12 CLA, modestly attenuated the induction of MCP1 to 79% of t10c12 CLA levels, and although COX2 mRNA levels were slightly lower, this latter difference was not significant (Fig. 2D-E) . In contrast, the SIRT1 inhibitors, sirtinol or nicotinamide, when used in combination with t10c12 CLA, attenuated the induction of the mRNA of MCP1 relative to t10c12 CLA control levels (Fig. 2D) . Similarly, sirtinol or nicotinamide, when used in combination with t10c12 CLA, attenuated the induction of the mRNA of COX2 relative to 10c12 CLA control levels (Fig. 2E) . These results indicated SIRT1 partially increased the induction of the inflammatory MCP1 and COX2 mRNAs, possibly through its inhibition of PPARc (see below), which plays an anti-inflammatory role in adipocytes [24] .
SIRT1 increases AMPK activity
We next determined whether SIRT1 affected AMPK regulation during the response to t10c12 CLA. AMPK activity was measured by the amount of phosphorylation at AMPK Thr172 (p-AMPK) and by the amounts of phosphorylated ACC (p-ACC), one of AMPK's key substrates in vivo [50] . We previously demonstrated the t10c12 CLA-stimulated increase in ACC phosphorylation was less in compound C treated adipocytes, supporting the premise that this phosphorylation was mediated by AMPK [9] . Although p-AMPK levels were increased by 2 h of treatment with t10c12 CLA, the addition of SIRT1 activator SRT1720 or SIRT inhibitors, had no significant effect on the amount of p-AMPK or p-ACC produced after 2 h of treatment (Fig. 3A) . However, when used in combination with t10c12 CLA for 12 h, SIRT1 activator SRT1720 significantly increased p-AMPK or p-ACC levels relative to the amounts present when treated by t10c12 CLA alone (Fig. 3B) . Conversely, when used in combination with t10c12 CLA for 12 h, SIRT1 inhibitors sirtinol or nicotinamide significantly attenuated p-AMPK levels relative to the amounts of these proteins in adipocytes treated with t10c12 CLA (Fig. 3B) . Similarly, when used in combination with t10c12 CLA, siRNA targeting of SIRT1 significantly reduced p-AMPK and p-ACC levels relative to the control treatment (Fig. 3C) . Collectively, these results indicated SIRT1 increased AMPK activity levels after 12 h, but not 2 h, of exposure to t10c12 CLA.
A PPARc agonist or antagonist affects the TG loss response to t10c12 CLA The involvement of PPARc in the TG loss response to t10c12 CLA was then tested through addition of a PPARc antagonist or agonist. The PPARc antagonist GW9662 significantly reduced TG levels when used in combination with 50 mM t10c12 CLA relative to TG levels in the t10c12 CLA treatment (Fig. 4A) . Prior to examining the effects of a PPARc agonist on the response to t10c12 CLA, we first determined that troglitazone was the most potent PPARc agonist amongst a set of four thiazolidinedione agonists, as measured by their ability to increase the amount of TG produced in differentiating adipocytes (Fig. 4B) . Troglitazone significantly attenuated t10c12 CLA's ability to reduce TG levels, as the combined treatment was not significantly different from the LA control (Fig. 4C) . These results indicated that, in adipocytes treated with t10c12 CLA, a PPARc antagonist facilitated TG loss while a PPARc agonist interfered with TG loss.
Cross regulation of PPARc and AMPK in adipocytes treated with t10c12 CLA
The cross regulation between PPARc and AMPK was next determined. When used in combination with t10c12 CLA for 12 h, PPARc antagonist GW9662 significantly increased AMPK and ACC phosphorylation levels (Fig. 4D) . Conversely, when used in combination with t10c12 CLA for 12 h, troglitazone significantly reduced AMPK and ACC phosphorylation levels (Fig. 4D) . However, when used in combination with t10c12 CLA for only 2 h there was no significant effect of these chemicals on AMPK or ACC phosphorylation levels (Fig. 4D) . Therefore, although AMPK activation occurred at 2 h, cross regulation by PPARc was not apparent at 2 h. Phosphorylation of PPARc increased by 140% at 12 h, but not by 2 h, after t10c12 CLA treatment (Fig. 4E-F) . When compound C was used in combination with t10c12 CLA, the amount of phosphorylated PPARc was reduced relative to the levels when treated by t10c12 CLA. This suggests AMPK activity was directly or indirectly involved in the phosphorylation of PPARc (Fig. 4F) . These results indicated AMPK and PPARc cross regulated each other in the response to t10c12 CLA.
Cross regulation of PPARc and AMPK also occurs in the absence of t10c12 CLA We next determined whether this cross regulation between AMPK and PPARc was a general aspect of these proteins by testing whether this occurred in the absence of t10c12 CLA. This was done by using two other chemicals to activate AMPK, alone or in combination with a PPARc agonist or antagonist. Phenformin, a strong AMPK activator, significantly reduced TG levels to 60% of those present in the untreated control adipocytes (Fig. 5A) . When phenformin was used in combination with troglitazone, significantly more TG was present than in adipocytes treated with phenformin alone (Fig. 5A) . Metformin, a weaker AMPK activator, only slightly reduced TG levels (Fig. 5B) . The TG level was further reduced when metformin was used in combination with the PPARc antagonist GW9662 (Fig. 5B) . These results indicated that the antagonistic cross regulation between AMPK and PPARc that was observed in the response to t10c12 CLA also occurred in phenformin or metformin treated adipocytes in the absence of t10c12 CLA.
NF-kB is deacetylated by one or more sirtuins in t10c12 CLA treated adipocytes
The regulation of SIRT1 activity by AMPK and PPARc was then assessed. A known deacetylation target of SIRT1 is Lys310 of the p65 subunit of NF-kB [38] . Therefore, we determined whether the p65 subunit of NF-kB changed its acetylation levels in response to t10c12 CLA. The acetylation level of the p65 subunit of NF-kB was not significantly changed by treatment with t10c12 CLA for 2 h (Fig. 6A) . In contrast, the amount of acetylated p65 subunit of NF-kB was significantly less in adipocytes treated with t10c12 CLA for 12 h (Fig. 6B) . When t10c12 CLA was used in combination with sirtinol or nicotinamide inhibitors of sirtuin activity, the amount of the acetylated p65 subunit of NF-kB was significantly higher relative to t10c12 CLA alone (Fig. 6 B) . These drug inhibition results supported the premise that one or more members of the sirtuin family of protein deacetylases were involved in the deacetylation of the p65 subunit of NF-kB. Of the seven sirtuin family members, only SIRT1 and SIRT6 have a nuclear localization [51] that overlaps with the subcellular localization of acetylated NF-kB. Additionally, of the seven sirtuins, only SIRT1 is known to deacetylate the p65 subunit of NF-kB [38] . Therefore, these results established that one or more members of the sirtuins, presumably at least SIRT1, were responsible for the deacetylation of the p65 subunit of NF-kB, and verified that sirtuin deacetylase activity increased in t10c12 CLA treated adipocytes.
AMPK and PPARc affect SIRT1 activity
The involvement of AMPK in regulating SIRT1 activity was then measured using compound C, an inhibitor of AMPK. The amount of the acetylated p65 subunit of NF-kB significantly increased in a treatment using t10c12 CLA in combination with compound C, relative to the acetylation level produced by t10c12 CLA (Fig. 6C ). This result indicated AMPK was directly or indirectly involved in regulating the SIRT1 deacetylation response to t10c12 CLA. The PPARc agonist troglitazone was used to determine whether PPARc affected the levels of acetylation of the p65 subunit of NF-kB. When used in combination with t10c12 CLA for 12 h, troglitazone-treated adipocytes significantly increased the amount of acetylated p65 subunit of NF-kB relative to the t10c12 CLA treatment, suggesting activated PPARc interferes with SIRT1 deacetylation activity (Fig. 6D) . Conversely, adipocytes treated with t10c12 CLA and the PPARc antagonist GW9662 significantly reduced the amounts of acetylated p65 subunit of NF-kB relative to the t10c12 CLA treatment, suggesting inhibition of PPARc increases SIRT1 deacetylation activity (Fig. 6D) . Collectively, these results indicated that AMPK positively regulated, and PPARc negatively regulated, SIRT1 activity in vivo, as measured by the deacetylation of the p65 subunit of NF-kB.
SIRT1 increases its binding to PPARc and NCoR1 in t10c12 CLA treated adipocytes
A possible mechanism for cross regulation of SIRT1 and PPARc is through participation within a common protein complex [35] . Using co-immunoprecipitation with a SIRT1 antibody, we observed that t10c12 CLA treatment resulted in a significant increase in the amount of a SIRT1/PPARc protein complex relative to the amount of this complex in the LA control, despite an overall reduction in PPARc protein levels in t10c12 CLA treated cells (Fig. 7) . Again using the same co-immunoprecipitation method, we observed that the amount of a protein complex containing SIRT1 and NCoR1 also significantly increased in the presence of t10c12 CLA (Fig. 7) . These results demonstrated that there was increased binding of SIRT1 to PPARc and NCoR1 in t10c12 CLA treated adipocytes.
Discussion
Here we demonstrated that SIRT1 activity was functionally involved in the TG loss response that occurred in t10c12 CLAtreated 3T3-L1 adipocytes. Our chemical inhibitor and activator studies indicated SIRT1 facilitated TG loss, as did AMPK, while PPARc stimulated TG synthesis (summarized in Figure 8 ). Our assays of protein activities, modifications, and interactions supported this functional data and provided molecular evidence of cross regulation between SIRT1, AMPK and PPARc in the response to t10c12 CLA. As discussed below, each of these proteins directly or indirectly affected the activity of the others.
In order to evaluate the effects of SIRT1 on specific pathways in lipid metabolism, we first established the effects of t10c12 CLA on lipid metabolism in our 3T3-L1 adipocyte system. The decrease in TG levels in t10c12 CLA-treated adipocytes was caused by a combination of reduced fatty acid biosynthesis, increased lipolysis, and increased fatty acid oxidation. Our finding that t10c12 CLAtreated adipocytes have increased p-AMPK levels and increased lipolysis and fatty acid oxidation is consistent with a report that activated AMPK increases lipolysis and fatty acid oxidation [22] . Our results were also consistent with the increased lipolysis and fatty acid oxidation, but not the increased fatty acid biosynthesis, reported in t10c12 CLA-treated 3T3-L1 adipocytes [6] . The latter difference may reflect differences in the specific cell cultures. The reduction in the rate of fatty acid synthesis was consistent with the reduced transcript levels of lipid biosynthetic enzymes such as ACC1, ACC2, and fatty acid synthase in mice and 3T3-L1 adipocytes [10, 15] , possibly mediated by AMPK's ability to phosphorylate and inhibit SREBP1, a key regulatory factor of these genes [52] . Further, the reduction in the rate of fatty acid synthesis was consistent with increased phosphorylation of ACC, which inhibits ACC (both ACC-1 and ACC-2 isoforms) and thereby inhibits production of malonyl-CoA. Reduced concentra- Figure 4 . PPARc antagonists and agonists affect TG levels and modulate p-AMPK activity levels in t10c12 CLA treated 3T3-L1 adipocytes. a Differentiated adipocytes were incubated with 50 mmol/L LA (L) or t10c12 CLA (C) with or without PPARc antagonist GW9662 (9662) for 24 h and TG levels were measured. b Differentiating adipocytes were treated with either control media (0), troglitazone (Tro), ciglitazone (C), rosiglitazone (R), or pioglitazone (P) to determine which PPARc agonist was most effective for increasing TG levels. c Differentiated 3T3-L1 adipocytes were incubated with 100 mmol/L LA or t10c12 CLA, with or without PPARc agonist troglitazone (Tro), and TG levels were measured after 24 h. d Adipocytes were treated as in a or c for 2 or 12 h using 100 mmol/L LA or t10c12 CLA, and representative western blots of cytosolic extracts indicate the proteins detected with antibodies to p-ACC (p-Ser79), total ACC, p-AMPK (p-Thr172), or total AMPK. The ratio of the phosphorylated to total form of each protein (phospho/total) is shown in the bar graphs. e-f The amount of phosphorylated or total PPARc in nuclear extracts was measured after 2 or 12 h of treatment with 100 mmol/L LA or t10c12 CLA, and with or without compound C (Comp. C) at 12 h. The ratio of the amount of phosphorylated to total PPARc is shown in the bar graphs. Each bar in panels a-f represents the mean + SEM (n = 3), and is representative of three independent experiments (a-c) or is the mean of three independent experiments (d-f). Means within each data type (a-e or u-x) not sharing a common letter differ, Pƒ0.05. doi:10.1371/journal.pone.0048874.g004
tions of malonyl-CoA should reduce the rate of fatty acid biosynthesis and increase the rate of fatty acid oxidation, as attenuated levels of malonyl-CoA no longer inhibit carnitine palmitoyltransferase-mediated transport of fatty acids into mitochondria for b-oxidation [18, 19, 50] . Fatty acid synthesis was also likely reduced by AMPK's ability to phosphorylate and inhibit fatty acid synthase [18, 19] . Our studies indicated that SIRT1 primarily affected the rate of fatty acid biosynthesis as inhibition of SIRT1 did not significantly affect the rate of lipolysis or fatty acid oxidation in the response to t10c12 CLA. Whether SIRT1 regulates fatty acid biosynthesis primarily via differential modulation of the activities of AMPK and PPARc or additionally through direct deacetylation of metabolic enzymes [53] requires additional research. Our results strongly support an increase in SIRT1 deacetylase activity occurs in vivo in t10c12 CLA treated adipocytes. We used the acetylation levels of Lys310 of the p65 subunit of NF-kB as an indicator of SIRT1 deacetylase activity in vivo. NF-kB/p65 had reduced amounts of acetylation at Lys310 in t10c12 CLA-treated adipocytes, indicating increased deacetylase activity was occurring. However, in principle Lys310 of p65/NF-kB can be deacetylated by both class I/II or sirtuin deacetylases [38] . Results with the sirtuin-specific inhibitors indicated the majority of NF-kB/p65 deacetylation was accomplished by the sirtuin class of deacetylases. Of the seven sirtuin family members, only SIRT1 and SIRT6 have the nuclear localization [51] needed to deacetylate nuclearlocalized NF-kB. Of these two candidates, SIRT1 is likely to be involved as SIRT1 physically binds to the p65 subunit of NF-kB and deacetylates it at Lys310 in human lung cells [38] . Further, our siRNA knockdown of SIRT1 indicates it is the major contributor to SIRT function in the t10c12 CLA response ( Figure 1E ). Therefore, our results strongly support an increase in the deacetylase activity of SIRT1 in t10c12 CLA-treated adipocytes, without ruling out minor contributions from other sirtuins.
The functional consequences of alterations in SIRT1, AMPK, and PPARc activities suggested there was cross-regulation between these proteins (summarized in Figure 8 ). Therefore, evidence for changes in protein modifications and/or activity was investigated. In the case of SIRT1 affecting AMPK, an activator of SIRT1 increased AMPK activity, while inhibitors of SIRT1 reduced AMPK activity in t10c12 CLA-treated adipocytes. A possible pathway connecting SIRT1 to AMPK is a SIRT1/ LKB1/AMPK axis by which SIRT1 can affect AMPK activity via deacetylation of protein kinase LKB1, which increases LKB1's ability to activate AMPK by phosphorylation [36, 37] . In the case of SIRT1 affecting PPARc, we found treatment with t10c12 CLA caused more SIRT1 to bind to PPARc and NCoR1. This is likely to inhibit PPARc activity as the increased binding of SIRT1 to PPARc and NCoR1 that occurred during fasting reduced PPARc transcriptional activity [35] . Reduced PPARc activity is consistent with the reduced transcription of lipogenic genes observed in t10c12 CLA treated adipocytes [10, 13, 15] . These results support a conclusion that SIRT1 stimulated AMPK activity and attenuated PPARc activity in t10c12 CLA treated adipocytes.
In the case of AMPK affecting SIRT1, inhibition of AMPK with compound C reduced SIRT1 activity as measured by the deacetylation of p65/NF-kB. The mechanism is unclear but could include AMPK-mediated changes in fatty acid oxidation which affect the NAD + /NADH ratio that affects SIRT1 activity [43] . In the case of AMPK affecting PPARc, AMPK was directly or indirectly responsible for the increased phosphorylated at Ser112 of PPARc in t10c12 CLA treated adipocytes [29] , as this effect was attenuated by the AMPK inhibitor compound C. Phosphorylation of PPARc at Ser112 facilitates its SUMOylation at K107, and thereby decreasing its transactivation activity [26] . These results support a conclusion that AMPK stimulated SIRT1 activity and attenuated PPARc activity in t10c12 CLA treated adipocytes.
In the case of PPARc affecting AMPK and SIRT1, troglitazone, a PPARc agonist, reduced the activities of AMPK and SIRT1. Conversely, GW9662, an antagonist of PPARc, increased the activities of AMPK and SIRT1. These results demonstrate that PPARc has a repressive effect on the activities of these proteins, which is consistent with the opposing roles of PPARc's in stimulating lipid biosynthesis and the catabolic energy-generating roles of AMPK and SIRT1 [30, 54] . The mechanisms of how PPARc affects AMPK and SIRT1 are unclear, despite the physical interaction between SIRT1 and PPARc [35, 55] . Although the mechanisms are unclear, PPARc affected the activity levels of SIRT1 and AMPK without changing the total amounts of these proteins in the response to t10c12 CLA. This suggests that PPARc achieved these effects via a non-transcriptional mechanism. As such, our results support an emerging role for PPARc in regulating non-genomic processes [27, 28] .
We also used AMPK activators in addition to t10c12 CLA to manipulate AMPK activity and explore whether cross regulation of AMPK and PPARc occurred in the absence of t10c12 CLA (summarized in Figure 8 ). Phenformin, a potent AMPK activator, caused a TG loss similar to that caused by t10c12 CLA treatment. Troglitazone, the most potent PPARc agonist in our 3T3-L1 adipocyte system, attenuated the TG loss caused by phenformin. Conversely, GW9662, a PPARc antagonist, increased the amount of TG loss when used with metformin, a moderate AMPK activator. This latter finding supports a hypothesis that both AMPK activation [9] and reduced PPARc activity [3] are important for reducing TG levels. Taken together, these results support a hypothesis that cross regulation between AMPK and PPARc also occurs in the absence of t10c12 CLA, and is therefore likely to generally occur between these proteins in adipocytes.
Both AMPK and SIRT1 play major roles in regulating cellular energy homeostasis and in response to caloric restriction [54, 56, 57] . The involvement of AMPK and SIRT1 in the response to t10c12 CLA is consistent with an overall similarity to cellular energy restriction. This is supported by the strong similarity of the whole genome transcriptional response of adipocytes treated with t10c12 CLA to the response caused by metformin [9] , which affects the cellular AMP/ATP ratio [58, 59] . Similarly, phenformin, which also affects the cellular AMP/ATP ratio, caused TG losses similar to those caused by t10c12 CLA and caused a whole genome transcriptional response similar to that of t10c12 CLA-treated adipocytes [17] . Our results indicated SIRT1 activation and cross regulation of AMPK occurred at 12 h but not as early as 2 h, while AMPK was activated at 2 h or earlier [9] . This is consistent with the suggestion that AMPK activation is a critical early event [9] . The signaling pathways used by t10c12 CLA to activate AMPK remain unknown. Figure S1 (TIF) Figure S2 (TIF) Figure S3 (TIF)
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